Evidence map›Paper›PMID 42027791›Full record

ArticleNature reviews bioengineering2026

Transparency of medical artificial intelligence systems.

Chanwoo Kim, Soham U Gadgil, Su-In Lee

Abstract read
In one paragraph

Article in Nature reviews bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Dissecting and directing pathology foundation models.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Materials and System Design for Self-Decision Bioelectronic Systems.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chanwoo KimPaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, USA.
Soham U GadgilPaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, USA.
Su-In LeePaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, USA.

Funding

Interpretable Machine Learning to Identify Alzheimer's Disease Therapeutic TargetsR01AG061132 · NIA · UNIVERSITY OF WASHINGTON · PI LEE, SU-IN · 2019 to 2023
$2.9M
IDEAL-XAI: Advancing Explainable AI to Identify Early Driver Events of Alzheimer's DiseaseRF1AG088824 · NIA · UNIVERSITY OF WASHINGTON · PI LEE, SU-IN · 2024 to 2024
$1.8M
XAI-TRUST: Explainable AI Techniques to Rigorously Understand, Scrutinize, and Trust Clinical AIR01EB035934 · NIBIB · UNIVERSITY OF WASHINGTON · PI Su-In Lee · 2024 to 2026
$1.3M
NIA NIH HHS R01 AG061132NIA NIH HHS RF1 AG088824NIBIB NIH HHS R01 EB035934
6 · The paper itself

Abstract

Artificial intelligence (AI) systems are now prevalent in our daily lives and hold promise for transforming high-stakes fields such as healthcare. Medical AI systems are showing significant potential to support diagnostics and treatment recommendations. As these systems play an increasingly significant role in clinical decision-making, ensuring transparency in their design, operation, and outcomes is essential for building trust among key stakeholders, including patients, providers, developers, and regulators. However, many systems still function as "black boxes," making it challenging for users-such as clinicians, patients, and other stakeholders-to interpret and verify their inner workings. Here, we examine the current state of transparency in medical AIs, identifying key challenges and risks these opaque systems pose. After motivating the need for transparency in all aspects of the machine learning pipeline, from training data to model development to model deployment, we explore a range of techniques that promote explainability throughout the pipeline while highlighting the importance of continual monitoring and system updates to ensure that AI systems remain reliable over time. Finally, we address the need to overcome barriers that inhibit the integration of transparency tools into clinical settings and review regulatory frameworks that prioritize transparency in emerging AI systems. Through this survey, we aim to increase awareness of current challenges and offer actionable insights for stakeholders, such as researchers, clinicians, and regulators, on how to build trustworthy and ethically responsible AI healthcare solutions.

Identifiers

PMID42027791
PMCPMC13102313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.